5 reports

ELI LILLY' S MIRIKIZIMAB IS A HUMANIZED MONOCLONAL ANTIBODY THAT SELECTIVELY BINDS TO THE P## SUBUNIT UNIQUE TO CYTOKINE IL-##, NEUTRALIZING ITS ACTIVITY.

  • Hospital
  • Medical Biotechnology
  • Monoclonal Antibody
  • Therapy
  • Remicade group
  • KEY COMPANIES IN THE ULCERATIVE COLITIS MARKET IN THE 7MM, 2015
  • 9.1 OVERVIEW

IT IS GUT-SELECTIVE MONOCLONAL ANTIBODY AND HAS SUPERIOR SAFETY PROFILE COMPARED TO ANTI-TNFS.

  • Autoimmune Disease
  • Epidemiology
  • Monoclonal Antibody
  • Therapy
  • Remicade group

PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF A HUMAN ANTI-IL-## monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.

  • Biosimilar
  • Epidemiology
  • Hospital
  • Monoclonal Antibody
  • Remicade group

December 2015: Morphotek, a subsidiary of Eisai, announces the results from the Study MORAb-##-## Phase ## trial assessing the safety and tolerability of its investigational monoclonal antibody, MORAb-##, in healthy subjects and those with mild to moderate RA.

  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Amgen Inc.
  • Remicade group
  • HUMIRA SWOT ANALYSIS, 2015

BIOGEN/ GENENTECH/ ROCHE' S RITUXAN (RITUXIMAB), MARKETED UNDER THE BRAND NAME MABTHERA OUTSIDE OF THE US, AND IS A CHIMERIC MURINE/ HUMAN MONOCLONAL ANTIBODY (MAB) USED FOR THE TREATMENT OF PATIENTS WITH ACTIVE GPA AND MPA.

  • Autoimmune Disease
  • Epidemiology
  • Monoclonal Antibody
  • Therapy
  • Remicade group